EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN study
Diogo Martins-Branco, Soraia Lobo-Martins, Philippe Aftimos, Bernardo Pereira, Leonor Vasconcelos de Matos, Leonor Fernandes, Elsa Campôa, Guilherme Nader-Marta, Michel Moreau, Donatienne Taylor, Francois P. Duhoux, Pedro Simões, Ana Rita Garcia, Vanessa Patel, Caterina Confente, Diogo Alpuim Costa, José Pereira, Catarina Santos, Marianne Paesmans, Frederico Sarmento, Teresa Gantes Padrão, Diana Simão, Daniel Bandarra, Berta Sousa, Margarida Brito, Andrea Gombos, Lieveke Ameye, Evandro de Azambuja
Springer Nature ·
2026-07-01
· DOI 10.1007/s10549-026-08012-5
The publisher did not provide an abstract — full text is available via the link below.
Diogo Martins-Branco, Soraia Lobo-Martins, Philippe Aftimos, Bernardo Pereira, Leonor Vasconcelos de Matos, Leonor Fernandes et al. EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN study. // Breast Cancer Research and Treatment. – 2026. – DOI: 10.1007/s10549-026-08012-5. – URL: https://doi.org/10.1007/s10549-026-08012-5
Diogo Martins-Branco, Soraia Lobo-Martins, Philippe Aftimos, Bernardo Pereira, Leonor Vasconcelos de Matos, Leonor Fernandes, Elsa Campôa, Guilherme Nader-Marta, Michel Moreau, Donatienne Taylor, Francois P. Duhoux, Pedro Simões, Ana Rita Garcia, Vanessa Patel, Caterina Confente, Diogo Alpuim Costa, José Pereira, Catarina Santos, Marianne Paesmans, Frederico Sarmento, Teresa Gantes Padrão, Diana Simão, Daniel Bandarra, Berta Sousa, Margarida Brito, Andrea Gombos, Lieveke Ameye, & Evandro de Azambuja (2026). EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN study. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-026-08012-5
Diogo Martins-Branco, et al. “EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN study.” Breast Cancer Research and Treatment, 2026. doi:10.1007/s10549-026-08012-5.
@article{MartinsBranco2026,
title = {EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN study},
author = {Martins-Branco, Diogo and Lobo-Martins, Soraia and Aftimos, Philippe and Pereira, Bernardo and Matos, Leonor Vasconcelos de and Fernandes, Leonor and Campôa, Elsa and Nader-Marta, Guilherme and Moreau, Michel and Taylor, Donatienne and Duhoux, Francois P. and Simões, Pedro and Garcia, Ana Rita and Patel, Vanessa and Confente, Caterina and Costa, Diogo Alpuim and Pereira, José and Santos, Catarina and Paesmans, Marianne and Sarmento, Frederico and Padrão, Teresa Gantes and Simão, Diana and Bandarra, Daniel and Sousa, Berta and Brito, Margarida and Gombos, Andrea and Ameye, Lieveke and Azambuja, Evandro de},
journal = {Breast Cancer Research and Treatment},
year = {2026},
doi = {10.1007/s10549-026-08012-5},
url = {https://doi.org/10.1007/s10549-026-08012-5}
}